See more : Canadian Life Companies Split Corp. (LFE.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Jounce Therapeutics, Inc. (JNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jounce Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tianjin You Fa Steel Pipe Group Stock Co., Ltd. (601686.SS) Income Statement Analysis – Financial Results
- BOOKOOK Securities Co., Ltd. (001270.KS) Income Statement Analysis – Financial Results
- Biglari Holdings Inc. (BH) Income Statement Analysis – Financial Results
- Gulf Oil Lubricants India Limited (GULFOILLUB.NS) Income Statement Analysis – Financial Results
- Daisue Construction Co., Ltd. (1814.T) Income Statement Analysis – Financial Results
Jounce Therapeutics, Inc. (JNCE)
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 103.27M | 88.98M | 78.69M | 67.14M | 70.05M | 67.80M | 34.90M | 22.13M | 11.24M |
| General & Administrative | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
| Other Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
| Cost & Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.09M | 2.83M | 3.40M | 3.85M | 3.83M | 4.42M | 1.94M | 1.47M | 1.11M |
| EBITDA | -50.16M | -91.06M | -45.12M | 52.82M | -23.50M | -11.99M | -11.76M | -27.06M | -9.41M |
| EBITDA Ratio | -61.16% | -338.41% | -72.37% | 35.72% | -36.05% | -16.73% | -31.61% | 0.00% | 0.00% |
| Operating Income | -52.24M | -91.06M | -45.12M | 52.82M | -31.29M | -19.22M | -14.47M | -30.40M | -16.21M |
| Operating Income Ratio | -63.71% | -338.41% | -72.37% | 35.72% | -48.00% | -26.82% | -38.89% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 3.96M | 2.81M | 763.00K | 1.86M | 5.70M |
| Income Before Tax | -50.78M | -90.86M | -43.83M | 56.87M | -27.33M | -16.41M | -13.70M | -28.53M | -10.52M |
| Income Before Tax Ratio | -61.93% | -337.67% | -70.31% | 38.46% | -41.92% | -22.90% | -36.84% | 0.00% | 0.00% |
| Income Tax Expense | 135.00K | 15.00K | 14.00K | 46.00K | 46.00K | 36.00K | 763.00K | 1.86M | 5.70M |
| Net Income | -50.92M | -90.87M | -43.84M | 56.82M | -27.38M | -16.44M | -13.70M | -28.53M | -10.52M |
| Net Income Ratio | -62.10% | -337.73% | -70.33% | 38.43% | -41.99% | -22.95% | -36.84% | 0.00% | 0.00% |
| EPS | -0.99 | -1.82 | -1.24 | 1.72 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
| EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
| Weighted Avg Shares Out | 51.68M | 49.93M | 35.43M | 33.08M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
| Weighted Avg Shares Out (Dil) | 51.68M | 49.93M | 35.43M | 34.29M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2020 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2020 Results - Earnings Call Transcript
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 -
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at several upcoming investor...
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board...
2 Biotech Stocks Poised to Soar in 2021
These baby biotechs are itching to come out of their shells.
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor...
Jounce Therapeutics: A Potential Roller Coaster
Jounce is developing several novel immunotherapies that target T cells and macrophages. I am bearish on the success of Vopratelimab and JTX-8064 and neutral on the prospects of JTX-4014 and JTX-1811.
Are Options Traders Betting on a Big Move in Jounce Therapeutics (JNCE) Stock?
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
Jounce Therapeutics Added to NASDAQ Biotechnology Index
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has been selected for addition to the...
Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president,...
Source: https://incomestatements.info
Category: Stock Reports